Published in Lancet on February 13, 2008
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology (2009) 3.25
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One (2009) 2.47
The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol (2008) 2.46
An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer (2011) 2.21
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.79
Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer (2012) 1.78
The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer (2010) 1.73
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
The inflammatory microenvironment in colorectal neoplasia. PLoS One (2011) 1.62
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res (2014) 1.52
Prognostic value of PLR in various cancers: a meta-analysis. PLoS One (2014) 1.50
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ (2013) 1.49
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics (2009) 1.34
Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol (2009) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw (2011) 1.29
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A (2009) 1.19
The role IL-1 in tumor-mediated angiogenesis. Front Physiol (2014) 1.19
Immunotherapy for metastatic solid cancers. Adv Surg (2011) 1.16
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol (2013) 1.13
The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol (2013) 1.12
Inflammation and cancer. World J Gastrointest Surg (2012) 1.12
Tumor-host interactions: the role of inflammation. Histochem Cell Biol (2008) 1.11
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
Inflammatory signaling and cellular senescence. Cell Signal (2008) 1.08
Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med (2013) 1.07
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol (2008) 1.05
Cancer invasion and metastasis: interacting ecosystems. Virchows Arch (2009) 1.05
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. Ann Oncol (2009) 1.04
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med (2013) 1.03
Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs (2009) 1.02
Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol (2009) 1.00
Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol (2011) 1.00
Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res (2012) 1.00
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol (2009) 1.00
Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol (2010) 0.99
Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia (2009) 0.98
Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio (2015) 0.97
The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond. J Leukoc Biol (2012) 0.97
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol (2010) 0.95
Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS One (2013) 0.95
Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity. J Immunol (2011) 0.92
Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs (2009) 0.92
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One (2014) 0.92
Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One (2012) 0.91
Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A (2014) 0.91
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep (2015) 0.88
Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. J Biol Chem (2010) 0.88
Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment. Mediators Inflamm (2010) 0.88
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res (2013) 0.88
The ambiguity in immunology. Front Immunol (2012) 0.87
Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment. Mar Drugs (2014) 0.87
Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer (2011) 0.87
Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87
Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res (2011) 0.86
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med (2008) 0.86
Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays. Int J Proteomics (2012) 0.85
Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. PPAR Res (2008) 0.85
RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Rep (2016) 0.85
Cytomegalovirus and tumors: two players for one goal-immune escape. Open Virol J (2011) 0.84
In silico tumor control induced via alternating immunostimulating and immunosuppressive phases. Virulence (2015) 0.84
Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J Ovarian Res (2016) 0.84
Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection. Oncol Rev (2012) 0.84
Mast cells as a potential prognostic marker in prostate cancer. Dis Markers (2013) 0.84
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res (2014) 0.83
Adult stem cels and their niches. Adv Exp Med Biol (2010) 0.83
Roles of CXCL5 on migration and invasion of liver cancer cells. J Transl Med (2014) 0.83
The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J (2014) 0.82
Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients. PLoS One (2014) 0.82
Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget (2015) 0.82
New take on comparative immunology: relevance to immunotherapy. Immunotherapy (2009) 0.82
Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis (2008) 0.82
CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology (2015) 0.82
Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma. PLoS One (2014) 0.81
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer (2015) 0.81
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines. Trends Parasitol (2013) 0.81
The Role of Stroma in Tumor Development. Cancer J (2015) 0.81
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int J Mol Sci (2016) 0.80
Lack of functional TSLP receptors mitigates Th2 polarization and the establishment and growth of 4T1 primary breast tumours but has different effects on tumour quantities in the lung and brain. Scand J Immunol (2013) 0.80
Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther (2015) 0.80
The evaluation of metallothionein expression in nasal polyps with respect to immune cell presence and activity. BMC Immunol (2010) 0.80
Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch (2012) 0.79
The Pathway Tools software. Bioinformatics (2002) 14.89
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity (2003) 4.93
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity (2008) 3.94
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Autoimmunity through cytokine-induced dendritic cell activation. Immunity (2004) 2.46
Dendritic cell subsets in health and disease. Immunol Rev (2007) 2.45
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med (2007) 2.25
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol (2003) 1.69
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Obstacles and opportunities in translational research. Nat Med (2005) 1.59
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57
Common cancer biomarkers. Cancer Res (2006) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood (2010) 1.55
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50
An immunologic portrait of cancer. J Transl Med (2011) 1.50
Humanized mice: are we there yet? J Exp Med (2005) 1.49
Research translation: a new frontier for clinical laboratories. Clin Chem Lab Med (2006) 1.48
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis (2005) 1.46
Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol (2004) 1.46
Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics (2004) 1.45
IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol (2007) 1.45
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44